Lysophosphatidylcholine perpetuates macrophage polarization toward classically activated phenotype in inflammation

Cellular Immunology

Volumn 289, Issue 1-2, 2014, Pages 185-190

  Qin, Xiaofei ^a   Qiu, Chunguang ^a   Zhao, Luosha ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Atherosclerosis; Inflammation; LysoPC; M1 macrophage

Indexed keywords

9 HYDROXYOCTADECADIENOIC ACID; ACID; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROLYSIS; INFLAMMATION; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; INFLAMMATION; LYSOPC; M1 MACROPHAGE;

ATHEROSCLEROSIS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL POLARITY; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; MACROPHAGES; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84900809024     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.04.010     Document Type: Article

References (20)

1. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
2. Fleetwood A.J., Lawrence T., Hamilton J.A., Cook A.D. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J. Immunol. 2007, 178:5245-5252.
3. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
4. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
5. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006, 177:7303-7311.
6. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
7. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 1992, 176:287-292.
8. Krausgruber T., Blazek K., Smallie T., Alzabin S., Lockstone H., Sahgal N., Hussell T., Feldmann M., Udalova I.A. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 2011, 12:231-238.
9. Satoh T., Takeuchi O., Vandenbon A., Yasuda K., Tanaka Y., Kumagai Y., Miyake T., Matsushita K., Okazaki T., Saitoh T., Honma K., Matsuyama T., Yui K., Tsujimura T., Standley D.M., Nakanishi K., Nakai K., Akira S. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 2010, 11:936-944.
10. Kennedy A., Fearon U., Veale D.J., Godson C. Macrophages in synovial inflammation. Front Immunol. 2011, 2:52.
11. Macaubas C., Nguyen K.D., Peck A., Buckingham J., Deshpande C., Wong E., Alexander H.C., Chang S.Y., Begovich A., Sun Y., Park J.L., Pan K.H., Lin R., Lih C.J., Augustine E.M., Phillips C., Hadjinicolaou A.V., Lee T., Mellins E.D. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin. Immunol. 2012, 142:362-372.
12. Qin J., Goswami R., Balabanov R., Dawson G. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J. Neurosci. Res. 2007, 85:977-984.
13. Shalhoub J., Falck-Hansen M.A., Davies A.H., Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J. Inflamm. (Lond.) 2011, 8:9.
14. Wu R., Svenungsson E., Gunnarsson I., Andersson B., Lundberg I., Schafer Elinder L., Frostegard J. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus 1999, 8:142-150.
15. Iwase M., Sonoki K., Sasaki N., Ohdo S., Higuchi S., Hattori H., Iida M. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis 2008, 196:931-936.
16. Zalewski A., Nelson J.J., Hegg L., Macphee C. Lp-PLA2: a new kid on the block. Clin. Chem. 2006, 52:1645-1650.
17. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 2001, 293:702-705.
18. Witte O.N., Kabarowski J.H., Xu Y., Le L.Q., Zhu K. Retraction. Science 2005, 307:206.
19. Chinetti-Gbaguidi G., Staels B. Macrophage polarization in metabolic disorders: functions and regulation. Curr. Opin. Lipidol. 2011, 22:365-372.
20. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.